Clinical trial
A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
NCT05683860 is registered in ClinicalTrials.gov with Wave Life Sciences USA, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
- Lead sponsor
- Wave Life Sciences USA, Inc.
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- December 14, 2022
- Completion date
- June 27, 2023
- Enrollment
- 8 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.